Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
Holding ATRC?
Track your performance easily
ATRC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.94 - $46.22
Previous Close$26.21
Volume488.00K
Average Volume (3M)879.45K
Market Cap
$1.26B
Enterprise Value$1.21B
Total Cash (Recent Filing)$114.02M
Total Debt (Recent Filing)$61.87M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Oct 30, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding48,697,505
10 Day Avg. Volume462,349
30 Day Avg. Volume879,445
Standard Deviation0.12
R-Squared0.37
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)7.53
Price to Sales (P/S)2.92
Price to Cash Flow (P/CF)42.60
P/FCF Ratio60.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.80
Enterprise Value/Gross Profit4.01
Enterprise Value/Ebitda-75.04
Forecast
1Y Price Target
$39.89Price Target Upside52.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Atricure News
Bulls Say, Bears Say
Bulls Say
Market PositionThe delay in Pulse Biosciences' PFA clamp eliminates a potential near-term competitive threat to ATRC's US Open-Heart Ablation business.
Product LaunchesAtriCure received FDA approval for the newest iteration of its clip, the Flex-Mini, and the impact from competition entering the LAA clipping market seems less than initially feared by investors.
Revenue GrowthThe company launched the cryoSphere+ in the US, which allows for a 25% reduction in freeze time – overcoming a key barrier to adoption and enables expansion into adjacent opportunities, like sternotomy.
Bears Say
Financial PerformanceATRC's gross, operating, and adjusted EBITDA margins were down 170 bps, 210 bps, and 120 bps Y/Y, respectively, with the gross margin decline driven by geographic and product mix.
Market ConcernsInvestors remain concerned with the potential impact of Medtronic's Penditure surgical left atrial appendage occlusion device on ATRC's US Appendage Management business.
Revenue GuidanceATRC lowered its FY24 revenue guidance, now expecting revenue in the range of $456M-$461M, driven by the shortfall of EPi-Sense revenue in Q2 and continued pressure expected through the rest of the year.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ATRC FAQ
What was Atricure’s price range in the past 12 months?
Atricure lowest stock price was $18.94 and its highest was $46.22 in the past 12 months.
What is Atricure’s market cap?
Currently, no data Available
When is Atricure’s upcoming earnings report date?
Atricure’s upcoming earnings report date is Oct 30, 2024 which is in 60 days.
How were Atricure’s earnings last quarter?
Atricure released its earnings results on Jul 30, 2024. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.168 by -$0.002.
Is Atricure overvalued?
According to Wall Street analysts Atricure’s price is currently Undervalued.
Does Atricure pay dividends?
Atricure does not currently pay dividends.
What is Atricure’s EPS estimate?
Atricure’s EPS estimate is -$0.2.
How many shares outstanding does Atricure have?
Atricure has 48,697,506 shares outstanding.
What happened to Atricure’s price movement after its last earnings report?
Atricure reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.168. Following the earnings report the stock price went down -1.955%.
Which hedge fund is a major shareholder of Atricure?
Among the largest hedge funds holding Atricure’s share is Royce & Associates LLC. It holds Atricure’s shares valued at 1M.
---
Atricure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.89 (52.19% Upside)
$39.89 (52.19% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 110.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $27.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.13%
12-Months-Change
Fundamentals
Return on Equity
-8.68%
Trailing 12-Months
Asset Growth
0.52%
Trailing 12-Months
Company Description
Atricure
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
---
ATRC Company Deck
---
ATRC Earnings Call
Q2 2024
0:00 / 0:00
---
ATRC Stock 12 Month Forecast
Average Price Target
$39.89
▲(52.19% Upside)
Technical Analysis
Best Analysts Covering ATRC
1 Year
1 Year Success Rate
19/21 ratings generated profit
1 Year Average Return
+41.73%
reiterated a buy rating last month
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +41.73% per trade.
---